Genitope (NASDAQ: GTOP) plans to issue a press release after 4:00 pm EST today that will discuss the initial results of its pivotal Phase 3 clinical trial examining GTOP's MyVax (personalized immunotherapy vaccine for follicular non-Hodgkin's lymphoma). GTOP is recently down $1.24 to $3.00. GTOP call option volume of 46,827 contracts compares to put volume of 6,584 contracts according to Track Data, suggesting large price risk.
Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com










